Acute Myocardial Infarction Associated With Yasmin Oral Contraceptive

Vessey MP , Doll R. Investigation of relation between use of oral contraceptives and thromboembolic disease. BMJ. 1968;2:199-205.

Sheldon T. Dutch GPs warned against new contraceptive pill . BMJ. 2002;324:869.

Inman Whw , Vessey MP , WesterholmB. , Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ. 1970;2:203-209.

Heinemann LA , Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf. 2004;27:1001-1018.

Shulman LP , Goldzieher JW The truth about oral contraceptives and venous thromboembolism. J Reprod Med. 2003;48(11 suppl):930-938.

Vaya A. , Mira Y. , Ferrando F. , Aznar J. Transient ischaemic attack associated with the new contraceptive Yasmin. Thrombosis Res. 2003;112:21.

Mira Y. , Morata C. , Vaya A. , Contreras T. , Aznar J. Is Yasmin as safe as other contraceptive pills? Clin Appl Thromb Hemost. 2006;12:378-379.

van Grootheest K. , Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ. 2003;326:257.

Vaya A. , Mira Y. , Ferrando F. , et al. Hyperlipidaemia and venous thromboembolism in patients lacking thrombophilic risk factors. Br J Haematol. 2002;118:255-259.

Doggen CJ , Smith NL , Lemaitre RN Serum lipid levels and the risk of venous thrombosis. Arterioscler Thromb Vasc Biol. 2004;24:1970-1975.

Spitzer WO , Faith JM , MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. Hum Reprod. 2002;17:2307-2314.

Kluft C. , Lansink M. Effect of oral contraceptives on hemostatic variables. Thromb Haemostasis. 1997;78:315-326.